EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic

T J von Oertzen, A Macerollo, M A Leone, E Beghi, M Crean, S Oztuk, C Bassetti, A Twardzik, D Bereczki, G Di Liberto, R Helbok, C Oreja-Guevara, A Pisani, A Sauerbier, J Sellner, R Soffietti, M Zedde, E Bianchi, B Bodini, F Cavallieri, L Campiglio, L F Maia, A Priori, M Rakusa, P Taba, E Moro, T M Jenkins, EANcore COVID-19 task force, T J von Oertzen, A Macerollo, M A Leone, E Beghi, M Crean, S Oztuk, C Bassetti, A Twardzik, D Bereczki, G Di Liberto, R Helbok, C Oreja-Guevara, A Pisani, A Sauerbier, J Sellner, R Soffietti, M Zedde, E Bianchi, B Bodini, F Cavallieri, L Campiglio, L F Maia, A Priori, M Rakusa, P Taba, E Moro, T M Jenkins, EANcore COVID-19 task force

Abstract

Background and purpose: The recent SARS-CoV-2 pandemic has posed multiple challenges to the practice of clinical neurology including recognition of emerging neurological complications and management of coexistent neurological diseases. In a fast-evolving pandemic, evidence-based studies are lacking in many areas. This paper presents European Academy of Neurology (EAN) expert consensus statements to guide neurologists caring for patients with COVID-19.

Methods: A refined Delphi methodology was applied. In round 1, statements were provided by EAN scientific panels (SPs). In round 2, these statements were circulated to SP members not involved in writing them, asking for agreement/disagreement. Items with agreement >70% were retained for round 3, in which SP co-chairs rated importance on a five-point Likert scale. Results were graded by importance and reported as consensus statements.

Results: In round one, 70 statements were provided by 23 SPs. In round two, 259/1061 SP member responses were received. Fifty-nine statements obtained >70% agreement and were retained. In round three, responses were received from 55 co-chairs of 29 SPs. Whilst general recommendations related to prevention of COVID-19 transmission had high levels of agreement and importance, opinion was more varied concerning statements related to therapy.

Conclusion: This is the first structured consensus statement on good clinical practice in patients with neurological disease during the COVID-19 pandemic that provides immediate guidance for neurologists. In this fast-evolving pandemic, a rapid response using refined Delphi methodology is possible, but guidance may be subject to change as further evidence emerges.

Keywords: COVID-19; chronic disease; human; neurology; practice guideline.

Conflict of interest statement

Dr von Oertzen is web editor in chief of the European Academy of Neurology (EAN), co‐chair of the EAN scientific panel for epilepsy. Dr M. Leone was associate editor of the European Journal of Neurology up to 2019. He is chair of the Guideline Production Group of the European Academy of Neurology. Pille Taba is co‐chair of the Infectious Diseases Panel of the European Academy of Neurology.

© 2020 The Authors. European Academy of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

References

    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
    1. WHO Director‐General’s opening remarks at the media briefing on COVID‐19 – 11 March 2020 [Internet]. [cited 2020 May 19]. .
    1. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77(6):683–690.
    1. Vonck K, Garrez I, Herdt VD, et al. Neurological manifestations and neuro‐invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2. Eur J Neurol 2020; 27:1578–1587.
    1. Moro E, Priori A, Beghi E, et al. The international EAN survey on neurological symptoms in patients with COVID‐19 infection. Eur J Neurol 2020;27 (9):1727–1737.
    1. Jin H, Hong C, Chen S, et al. Consensus for prevention and management of coronavirus disease 2019 (COVID‐19) for neurologists. Stroke Vasc Neurol 2020; 5(2):146–151.
    1. Rubin MA, Bonnie RJ, Epstein L, et al. AAN position statement: the COVID‐19 pandemic and the ethical duties of the neurologist. Neurology 2020.95 (4):167–172.
    1. Aggour M, White P, Kulcsar Z, Fiehler J, Brouwer P. European Society of Minimally Invasive Neurological Therapy (ESMINT) recommendations for optimal interventional neurovascular management in the COVID‐19 era. J NeuroIntervent Surg 2020; 12: 542–544.
    1. Bernhardt D, Wick W, Weiss SE, et al. Neuro‐oncology management during the COVID‐19 pandemic with a focus on WHO grades III and IV gliomas. Neuro Oncol 2020;22 (7):928–935.
    1. Dubbioso R, Nobile‐Orazio E, Manganelli F, et al. Dealing with immune‐mediated neuropathies during COVID‐19 outbreak: practical recommendations from the task force of the Italian Society of Neurology (SIN), the Italian Society of Clinical Neurophysiology (SINC) and the Italian Peripheral Nervous System Association (ASNP). Neurol Sci 2020; 41: 1345–1348.
    1. Jacob S, Muppidi S, Guidon A, et al. Guidance for the management of myasthenia gravis (MG) and Lambert–Eaton myasthenic syndrome (LEMS) during the COVID‐19 pandemic. J Neurol Sci 2020; 412: 116803.
    1. Miocinovic S, Ostrem JL, Okun MS, et al Recommendations for deep brain stimulation device management during a pandemic. J Parkinson’s Dis 2020;10 (3):903–910.
    1. AHA/ASA Stroke Council Leadership . Temporary emergency guidance to US stroke centers during the coronavirus disease 2019 (COVID‐19) pandemic. Stroke 2020; 51: 1910–1912.
    1. Solé G, Salort‐Campana E, Pereon Y, et al. Guidance for the care of neuromuscular patients during the COVID‐19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Rev Neurol (Paris) 2020; 176: 507–515.
    1. Sharma D, Rasmussen M, Han R, et al. Anesthetic management of endovascular treatment of acute ischemic stroke during COVID‐19 pandemic: consensus statement from Society for Neuroscience in Anesthesiology & Critical Care (SNACC): endorsed by Society of Vascular & Interventional Neurology (SVIN), Society of Neurointerventional Surgery (SNIS), Neurocritical Care Society (NCS), European Society of Minimally Invasive Neurological Therapy (ESMINT) and American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) cerebrovascular section. J Neurosurg Anesthesiol 2020; 32: 193–201.
    1. Flexman AM, Abcejo AS, Avitsian R, et al. Neuroanesthesia practice during the COVID‐19 pandemic: recommendations from Society for Neuroscience in Anesthesiology and Critical Care (SNACC). J Neurosurg Anesthesiol 2020; 32: 202–209.
    1. RECOVERY Collaborative Group , Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid‐19 – Preliminary report. N Engl J Med 2020; NEJMoa2021436. 10.1056/NEJMoa2021436.
    1. Sellner J, Taba P, Öztürk S, Helbok R. The need for neurologists in the care of COVID‐19 patients. Eur J Neurol 2020;27 (9):e31–e32.
    1. Moro E, Deuschl G, de Visser M, et al. A call from the European Academy of Neurology on COVID‐19. Lancet Neurol 2020; 19(6): 482.
    1. von Oertzen TJ. COVID‐19 – neurologists stay aware! Eur J Neurol 2020;27 (9):1710–1711.
    1. Zolk O, Hafner S, Schmidt CQ, on behalf of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) . COVID‐19 pandemic and therapy with ibuprofen or renin‐angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments. Naunyn‐Schmiedeberg's Arch Pharmacol 2020; 393: 1131–1135.
    1. Hartung H‐P, Aktas O. COVID‐19 and management of neuroimmunological disorders. Nat Rev Neurol 2020;16: 347–348.
    1. Berger JR, Brandstadter R, Bar‐Or A. COVID‐19 and MS disease‐modifying therapies. Neurol Neuroimmunol Neuroinflamm 2020; 7(4): e761.
    1. Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID‐19 pandemic. Mult Scler Relat Disord 2020; 43: 102174.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren